ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SNY vs BMY // EV/EBITDA & P/E VALUATION

Sanofi ADS (NASDAQ) VS. Bristol-Myers Squibb Company (NYSE) • 15-METRIC TALLY: SNY 3 — BMY 9
▲ EV/EBITDA & P/E VALUATION LEADER: BMY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SNY VS. BMY) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SNY BMY SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 71.10% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% 13.30% -3.40 BMY /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 21.0x 16.3x +4.70 BMY /valuation <GO>
Free Cash Flow Yield 2.21% 10.24% -8.03 BMY /fcf-yield <GO>
Operating Margin 13.90% 17.90% -4.00 BMY /operating-margins <GO>
Net Profit Margin 10.90% 14.60% -3.70 BMY /net-margins <GO>
Revenue Growth (YoY) -1.10% -0.20% -0.90 BMY /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 4.02% -4.02 BMY /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 2.24 +1.50 SNY /balance-sheet <GO>
Piotroski F-Score Quality 7/9 7/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 58.8 50.4 +8.40 SNY /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.14 0.98 +0.16 SNY /macro-sensitivity <GO>
Forward P/E Multiple 30.5x 16.6x +13.90 BMY /forward-pe <GO>
Enterprise Scale & Market Cap $105.19B $125.40B -$20.21B BMY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SNY REV BMY REV SNY GROSS % BMY GROSS % SNY FCF BMY FCF
FY 2025 — $48.19B — 71.1% — $12.85B
FY 2024 — $48.30B — 71.1% — $13.94B
FY 2023 — $45.01B — — — $11.83B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SNY // BETA 1.14
BMY // BETA 0.98